Navigation Links
Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials
Date:5/4/2010

l back up compounds modulate sigma receptors and may guard against oxidative stress and mitochondrial dysfunction via ion signaling modulation. So far the compounds have performed extremely well in well-recognized animal models of Alzheimer's disease, underscoring the promise of the company's new alternative approach to the disease.

ANAVEX's SIGMACEPTOR(TM)-C program involves the development of novel and original drug candidates targeting cancer. The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid cancers. Several of the company's compounds have demonstrated an ability to significantly delay the growth of cancerous tumors in patient-derived xenografts in advanced preclinical studies.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements in this press release include that our drug compounds show promise to combat certain diseases. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file an IND or commence clinical studies. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
2. Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
3. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
4. Anavex strengthens Board of Directors
5. Anavex advances drug candidate for treatment of Alzheimers disease
6. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Viron reports positive proof of concept results in arthritis for its VT-346 anti-TNF therapeutic
9. BMP Sunstone Reports Fourth Quarter and Full Year 2009 Financial Results
10. American Oriental Bioengineering Reports Fourth Quarter and Full Year 2009 Financial Results
11. The Cancer Market Outlook To 2014: Competitive Landscape, Market Size, Pipeline Analysis and Growth Opportunities Now Available on ReportsandReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... but one of the most promising technologies for future ... light (photons) instead of electrons. First, it is necessary ... photons and control their direction. Researchers around the world ... control, but now scientists at the Niels Bohr Institute ... emitted one at a time and in a particular ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... be valued at $5.6 billion in 2019. It ... 18.1% from 2013 to 2019, and was valued ... research report published by Transparency Market Research. , ... please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to a ... Market” the global orthobiologics market was valued at USD 3,754.6 ... worth USD 5,519.9million in 2019at a CAGR of 5.9% from ... 50 years and above is afflicted by bone and joint ... the year 2020. This has and will continue to increase ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... 16 /PRNewswire-FirstCall/ Carrington Laboratories,Inc., a global provider of ... that it received a letter from The,Nasdaq Stock ... to,delist the securities of the Company, and would ... the open of business on Thursday, August,16, 2007. ...
... for Anesiva - ... a.m. ET -, SOUTH SAN FRANCISCO, Calif., Aug. ... that the U.S. Food and Drug,Administration (FDA) has approved ... rapid,topical, local analgesia to reduce the pain associated with ...
... ANGELES, Aug. 17 Digital Union announced today ... of SERGG (Southeast,Regional Genetics Group) in Region 3 ... eight southeastern states, Puerto Rico and the,US Virgin ... HRSA,since 2004, has received additional funding for another ...
Cached Biology Technology:Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 2Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 3Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 4Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children 5Digital Union's RT1(TM) Software Creates Telegenetics Network for Region 3 Genetics Collaborative 2
(Date:8/29/2014)... have made some surprising discoveries about the body,s ... virus (SIV), the team found that specialized cells ... responders to viral invasion and are the source ... interleukin-1 beta (IL-1β). , Though aimed at ... the gut epithelium that provides a barrier to ...
(Date:8/29/2014)... at the Barshop Institute for Longevity and Aging Studies, ... Health Science Center at San Antonio, have found another ... rodent, the naked mole rat. , They reported ... rats protects and alters the activity of the proteasome, ... The factor also protects proteasome function in human, mouse ...
(Date:8/29/2014)... MISSOULA Until recently, little has been known about ... An international team of scientists, one of whom is ... breakthrough by showing that genes controlling the development of ... for rabbit domestication., The study was published Aug. 28 ... genetic questions. It is online at http://www.sciencemag.org/ ., ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... that some strains of algae, when starved of nutrients, quickly ... the discovery lay dormant until people began to search in ... early 2000s, algal fuel production enjoyed a tremendous vogue, as ... converting "pond scum" to oil. But a recent wave of ...
... 13, 2011 Studies have estimated that converting manure from the ... renewable energy equal to 8 billion gallons of gasoline, or ... Because more and more farmers and communities are interested in ... need for information on the economic feasibility and sustainability of ...
... This press release is available in German . ... long been assumed. This is the conclusion of a study in ... of four major European rivers. It was revealed that 38 per ... have an effect on organisms. According to scientists writing in the ...
Cached Biology News:WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 2WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 3WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 4Does converting cow manure to electricity pay off? 2Pesticides pollute European waterbodies more than previously thought 2Pesticides pollute European waterbodies more than previously thought 3Pesticides pollute European waterbodies more than previously thought 4
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
Hybridization cassette for one slide...
... are selected tissues from mouse, rat, and ... in paraffin, sectioned and mounted onto slides. ... ready for use in tissue RNA localization ... slides are suitable for in situ hybridization ...
Biology Products: